| Literature DB >> 20129150 |
Anthony D Harries1, Rony Zachariah, Joep J van Oosterhout, Steven D Reid, Mina C Hosseinipour, Vic Arendt, Zengani Chirwa, Andreas Jahn, Erik J Schouten, Kelita Kamoto.
Abstract
Despite the enormous progress made in scaling up antiretroviral therapy (ART) in sub-Saharan Africa, many challenges remain, not least of which are the identification and management of patients who have failed first-line therapy. Less than 3% of patients are receiving second-line treatment at present, whereas 15-25% of patients have detectable viral loads 12 months or more into treatment, of whom a substantial proportion might have virological failure. We discuss the reasons why virological ART failure is likely to be under-diagnosed in the routine health system, and address the current difficulties with standard recommended second-line ART regimens. The development of new diagnostic tools for ART failure, in particular a point-of-care HIV viral-load test, combined with simple and inexpensive second-line therapy, such as boosted protease-inhibitor monotherapy, could revolutionise the management of ART failure in resource-limited settings. 2010 Elsevier Ltd. All rights reserved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20129150 DOI: 10.1016/S1473-3099(09)70321-4
Source DB: PubMed Journal: Lancet Infect Dis ISSN: 1473-3099 Impact factor: 25.071